1.Enzyme-directed Immobilization Strategies for Biosensor Applications
Xing-Bao WANG ; Yao-Hong MA ; Yun-Long XUE ; Xiao-Zhen HUANG ; Yue SHAO ; Yi YU ; Bing-Lian WANG ; Qing-Ai LIU ; Li-He ZHANG ; Wei-Li GONG
Progress in Biochemistry and Biophysics 2025;52(2):374-394
		                        		
		                        			
		                        			Immobilized enzyme-based enzyme electrode biosensors, characterized by high sensitivity and efficiency, strong specificity, and compact size, demonstrate broad application prospects in life science research, disease diagnosis and monitoring, etc. Immobilization of enzyme is a critical step in determining the performance (stability, sensitivity, and reproducibility) of the biosensors. Random immobilization (physical adsorption, covalent cross-linking, etc.) can easily bring about problems, such as decreased enzyme activity and relatively unstable immobilization. Whereas, directional immobilization utilizing amino acid residue mutation, affinity peptide fusion, or nucleotide-specific binding to restrict the orientation of the enzymes provides new possibilities to solve the problems caused by random immobilization. In this paper, the principles, advantages and disadvantages and the application progress of enzyme electrode biosensors of different directional immobilization strategies for enzyme molecular sensing elements by specific amino acids (lysine, histidine, cysteine, unnatural amino acid) with functional groups introduced based on site-specific mutation, affinity peptides (gold binding peptides, carbon binding peptides, carbohydrate binding domains) fused through genetic engineering, and specific binding between nucleotides and target enzymes (proteins) were reviewed, and the application fields, advantages and limitations of various immobilized enzyme interface characterization techniques were discussed, hoping to provide theoretical and technical guidance for the creation of high-performance enzyme sensing elements and the manufacture of enzyme electrode sensors. 
		                        		
		                        		
		                        		
		                        	
2.Practice and evaluation of pharmacists’participation in long-term MTM models for stroke patients based on family doctor system
Lu SHI ; Chun LIU ; Lian TANG ; Jingjing LI ; Sudong XUE ; Yanxia YU ; Wenwen LI ; Keren YU ; Jianhui XUE ; Wen MA ; Hongzhi XUE
China Pharmacy 2025;36(9):1129-1134
		                        		
		                        			
		                        			OBJECTIVE To investigate the clinical efficacy of integrating pharmacists into family health teams (FHTs) for long-term medication therapeutical management (MTM) in stroke patients, and empirically evaluate the service model. METHODS A pharmacist team, jointly established by clinical and community pharmacists from the Affiliated Suzhou Hospital of Nanjing Medical University (hereinafter referred to as “our hospital”), developed a pharmacist-supported MTM model integrated into FHTs. Using a prospective randomized controlled design, 170 stroke patients discharged from our hospital (July 2022-December 2023) and enrolled in FHTs at Suzhou Runda Community Hospital were randomly divided into trial group (88 cases) and control group (82 cases) according to random number table. The control group received routine FHTs care (without pharmacist involvement in the team collaboration), while the trial group xhz8405@126.com received 12-month MTM services supported by pharmacists via an information platform. These services specifically included innovative interventions such as personalized medication regimen optimization based on the MTM framework, dynamic medication adherence management, medication safety monitoring, a home medication assessment system, and distinctive service offerings. Outcomes of the 2 grousp were compared before and after intervention, involving medication adherence (adherence rate, adherence score), compliance rates for stroke recurrence risk factors [blood pressure, low-density lipoprotein cholesterol (LDL-C)], and incidence of adverse drug reactions (ADR). RESULTS After 12 months, the trial group exhibited significantly higher medication adherence rates, improved adherence scores, higher compliance rates for blood pressure and LDL-C targets compared to the control group (P<0.05). The incidence of ADR in the trial group (4.55%) was significantly lower than that in the control group (8.11%), though the difference was not statistically significant (P> 0.05). CONCLUSIONS Pharmacist involvement in FHTs to deliver MTM services significantly enhances medication adherence and optimizes risk factor for stroke recurrence, offering practical evidence for advancing pharmaceutical care in chronic disease management under the family doctor system.
		                        		
		                        		
		                        		
		                        	
3.Identification of Complex and Combined Antibody Consisted of Anti-c, Anti-E, Anti-Jka and Anti-Fya.
Ting-Ting MA ; Xue-Jun LIU ; Bao-Jia HUANG ; Yan ZHOU ; Qiu-Hong MO ; Zhou-Lin ZHONG ; Jin-Lian LIU
Journal of Experimental Hematology 2023;31(5):1475-1480
		                        		
		                        			OBJECTIVE:
		                        			To investigate the role of multiple serological methods in the identification of complex antibodies.
		                        		
		                        			METHODS:
		                        			The blood group antigens were detected by saline and microcolumn agglutination methods. The saline method was used to screen and identify IgM-type antibodies in the patient's serum, while the polybrene, anti-globulin, microcolumn agglutination, enzymic and absorption-elution methods were used to screen and identify IgG-type antibodies.
		                        		
		                        			RESULTS:
		                        			The patient was B/CCDee/Jk(a-b+)/Fy(a-b+) blood type. The serum reacted with panel cells, and the reaction presented anti-E pattern in the saline medium. It was fully positive in the microcolumn agglutination card, except 2 negative ones after using papain to treat the panel cells. Referring to the pattern table, it was concluded that there existed anti-c, anti-E, and anti-Jka antibodies, and one antibody corresponding to an antigen that was easily destroyed by papain. The red blood cells with specific phenotype were selected for absorption-elution to identify IgG-type anti-c, anti-E, anti-Jka and anti-Fya antibodies.
		                        		
		                        			CONCLUSION
		                        			It is confirmed that IgM-type anti-E, and IgG-type anti-c, anti-E, anti-Jka and anti-Fya antibodies exist in the patient's serum by multiple serological methods.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Papain
		                        			;
		                        		
		                        			Blood Group Antigens
		                        			;
		                        		
		                        			Erythrocytes
		                        			;
		                        		
		                        			Immunoglobulin G
		                        			;
		                        		
		                        			Immunoglobulin M
		                        			
		                        		
		                        	
4.Study on the application of model transfer technology in the extraction process of Xiao'er Xiaoji Zhike oral liquid
Xiu-hua XU ; Lei NIE ; Xiao-bo MA ; Xiao-qi ZHUANG ; Jin ZHANG ; Hai-ling DONG ; Wen-yan LIANG ; Hao-chen DU ; Xiao-mei YUAN ; Yong-xia GUAN ; Lian LI ; Hui ZHANG ; Xue-ping GUO ; Heng-chang ZANG
Acta Pharmaceutica Sinica 2023;58(10):2900-2908
		                        		
		                        			
		                        			 The modernization and development of traditional Chinese medicine has led to higher standards for the quality of traditional Chinese medicine products. The extraction process is a crucial component of traditional Chinese medicine production, and it directly impacts the final quality of the product. However, the currently relied upon methods for quality assurance of the extraction process, such as simple wet chemical analysis, have several limitations, including time consumption and labor intensity, and do not offer precise control of the extraction process. As a result, there is significant value in incorporating near-infrared spectroscopy (NIRS) in the production process of traditional Chinese medicine to improve the quality control of the final products. In this study, we focused on the extraction process of Xiao'er Xiaoji Zhike oral liquid (XXZOL), using near-infrared spectra collected by both a Fourier transform near-infrared spectrometer and a portable near-infrared spectrometer. We used the concentration of synephrine, a quality control index component specified by the pharmacopoeia, to achieve rapid and accurate detection in the extraction process. Moreover, we developed a model transfer method to facilitate the transfer of models between the two types of near-infrared spectrometers (analytical grade and portable), thus resolving the low resolution, poor performance, and insufficient prediction accuracy issues of portable instruments. Our findings enable the rapid screening and quality analysis of XXZOL onsite, which is significant for quality monitoring during the traditional Chinese medicine production process. 
		                        		
		                        		
		                        		
		                        	
5.Prognosis of adenoid cystic carcinoma of head and neck and risk factors for lung metastasis.
Xue Lian WANG ; Meng Jiao ZHOU ; Ting Yao MA ; Ling Yan JIANG ; Qi Dong ZHAO ; Hong Bo XU ; Jing ZHOU ; Li Feng LI ; Lu KONG ; Xiaohong CHEN
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2022;57(8):963-968
		                        		
		                        			
		                        			Objective: To analyze the prognosis and risk factors of lung metastasis of patients with adenoid cystic carcinoma(ACC) of head and neck. Methods: A retrospective study was conducted. The data of 157 patients with ACC of head and neck treated in Beijing Tongren Hospital, Capital Medical University from January 2014 to October 2020 were collected, including 72 males and 85 females, with onset age between 14 and 72 years old. According to whether lung metastasis occurred, the patients were divided into lung metastasis group (88 cases) and non-pulmonary metastasis group (69 cases). Kaplan-Meier method was used to calculate the overall survival rate and progression-free survival rate using SPSS 26.0 software. Log-rank test was used to evaluate statistically relevant clinicopathological factors. Cox proportional risk model was used in multivariate analysis for the factors affecting the lung metastasis-free survival using R Studio 1.2.5042. Results: The 3-year and 5-year overall survival rates were 91.5% and 85.2%, respectively. The 3-year and 5-year progression-free survival rates were 57.7% and 34.3%, respectively. Univariate analysis showed that primary site, histological grade, high-grade transformation, Ki-67, T stage, and lymph node status were the risk factors for lung metastasis (χ2=11.78, 10.41, 4.06, 4.71, 5.37, 16.20, respectively, all P<0.05). Multivariate analysis showed independent risk factors for lung metastasis, including submandibular gland and sublingual gland (HR=3.53, 95%CI: 1.19-10.46, P<0.05), T3-4 stage (HR=3.09, 95%CI: 1.54-6.23, P<0.05), and Grade Ⅱ-Ⅲ grade (HR=2.47, 95%CI: 1.26-4.86,P<0.05). Conclusion: Distant metastasis, mainly pulmonary metastasis, affects the long-term prognosis of patients with ACC significantly. Primary site, T stage and histopathological grade can be used as the predictors for the risk of lung metastasis.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Carcinoma, Adenoid Cystic
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Lung/pathology*
		                        			;
		                        		
		                        			Lung Neoplasms/secondary*
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Prognosis
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Risk Factors
		                        			;
		                        		
		                        			Young Adult
		                        			
		                        		
		                        	
6.Investigation on status of dyslipidemia in Chinese females aged 35 years or above.
Ming Yan MA ; Xue Lian CHEN ; Zuo CHEN ; Xin WANG ; Lin Feng ZHANG ; Su Ning LI ; Cong Yi ZHENG ; Yu Ting KANG ; Hao Qi ZHOU ; Lu CHEN ; Xue CAO ; Ji Hong HU ; Zeng Wu WANG
Chinese Journal of Cardiology 2022;50(5):486-493
		                        		
		                        			
		                        			Objective: To investigate the prevalence, awareness, treatment and control status of dyslipidemia among females aged ≥35 years old across China. Methods: Participants were selected by stratified multistage random sampling method in the "Twelfth Five-Year Plan" National Science and Technology Support Project "Survey on the Prevalence of Important Cardiovascular Diseases and Key Technology Research in China" project. This study is a retrospective, cross-sectional study. A total of 17 418 females aged 35 years and over were included in the current study. The basic information such as age, medical history and menopause was collected by questionnaire. The blood lipid parameters were derived from clinical laboratory examinations. The prevalence of dyslipidemia and the rate of awareness, treatment, and control of dyslipidemia were analyzed in females aged 35 years and over. Results: The age of participants was (56.2±13.0) years old, and the prevalence of dyslipidemia was 33.1% (5 765/17 418). The prevalence rates of high total cholesterol, hypertriglyceridemia, low HDL-C and high LDL-C were 9.7% (1 695/17 418), 11.1% (1 925/17 418), 10.9% (1 889/17 418) and 7.3% (1 262/17 418), respectively. The prevalence of dyslipidemia increased with age and the prevalence of dyslipidemia in women who were not married, Han, menarche age>16 years, obesity, central obesity, alcohol consumption, diabetes, hypertension and family history of cardiovascular disease were higher than those without such characteristics (P<0.05). There were 10 432 (59.9%) menopausal females in this cohort and prevalence of dyslipidemia of these participants was 38.8% (4 048/10 432), which was higher than that of non-postmenopausal females (24.6%, 1 717/6 986) (P<0.05). The awareness rates, treatment rates and control rates of dyslipidemia were 33.9% (1 953/5 765), 15.1% (870/5 765) and 2.5% (143/5 765) respectively among females aged 35 years and over in China. Conclusion: The prevalence of dyslipidemia in Chinese females aged 35 years and over is high, and its awareness, treatment, and control rates need to be optimized.
		                        		
		                        		
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Cardiovascular Diseases
		                        			;
		                        		
		                        			China/epidemiology*
		                        			;
		                        		
		                        			Cross-Sectional Studies
		                        			;
		                        		
		                        			Dyslipidemias/epidemiology*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Obesity/epidemiology*
		                        			;
		                        		
		                        			Prevalence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Risk Factors
		                        			
		                        		
		                        	
7.Performance of point-of-care testing for cervical cancer screening.
Suang ZHAO ; Xue Lian ZHAO ; Shang Ying HU ; Jun Fei MA ; Cai Feng SU ; De Bin WANG ; Xun ZHANG ; Fang Hui ZHAO
Chinese Journal of Preventive Medicine 2022;56(2):165-170
		                        		
		                        			
		                        			Objective: To evaluate the performance of point-of-care testing for cervical cancer and precancerous lesions screening. Methods: In September 2020, 197 and 273 women were selected by using simple random sampling method from "self-sampling" cohort and "physician-sampling" cohort established in Xiangyuan county, Shanxi Province, China, respectively. Cervical exfoliated cells were collected by women themselves or gynecologists. All samples were detected by POCT and women with positive result were directly referred for colposcopy. Subsequently, all the samples were detected by careHPV and PCR test. Colposcopy and punch biopsy were performed for women with POCT negative but careHPV or PCR test positive at another visit. Using histopathological diagnosis as the gold standard, we calculated sensitivity, specificity and drew the receiver operating characteristic (ROC) curves. The accuracy of POCT was analyzed and compared to that of careHPV and conventional PCR test in cervical cancer and precancerous lesions screening. Results: The median (Q1 , Q3) age of 470 women was 51 (45, 57) years old. Based on self-sampling, the sensitivity and specificity of POCT for CIN2+ were 100.00% (95%CI: 56.56%-100.00%) and 28.95% (95%CI: 22.97%-35.76%), respectively. Compared with POCT, POCT HPV16/18 test had similar sensitivity and higher specificity of 89.47% (95%CI: 84.30%-93.08%). Self-sampling POCT HPV16/18 test had an AUC of 0.947 (95%CI:0.910-0.985), which was higher than that of careHPV and PCR test. Physician-sampling POCT test had 100.00% sensitivity (95%CI: 64.57%-100.00%) and 55.85% specificity (95%CI: 49.83%-61.70%) for detecting CIN2+. POCT HPV16/18 test had lower sensitivity (71.43%, 95%CI: 35.90%-91.76%) and higher specificity (92.45%, 95%CI: 88.63%-95.06%). POCT HPV16/18 test generally showed similar AUC on both self-collected samples and clinician-collected samples (0.947 vs 0.819, P=0.217). Conclusion: POCT HPV16/18 test is an effective method with relatively high sensitivity and specificity for cervical cancer screening.
		                        		
		                        		
		                        		
		                        			Cervical Intraepithelial Neoplasia/diagnosis*
		                        			;
		                        		
		                        			Colposcopy
		                        			;
		                        		
		                        			Early Detection of Cancer/methods*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Human papillomavirus 16/genetics*
		                        			;
		                        		
		                        			Human papillomavirus 18
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Mass Screening/methods*
		                        			;
		                        		
		                        			Papillomaviridae
		                        			;
		                        		
		                        			Papillomavirus Infections/diagnosis*
		                        			;
		                        		
		                        			Point-of-Care Testing
		                        			;
		                        		
		                        			Pregnancy
		                        			;
		                        		
		                        			Sensitivity and Specificity
		                        			;
		                        		
		                        			Uterine Cervical Neoplasms
		                        			
		                        		
		                        	
8.Evaluation of safety and immunogenicity of hepatitis E vaccine in maintenance hemodialysis patients.
Xue Lian WANG ; Yan Ting LI ; Xin Jing MA ; Yi Sheng LING ; Ting WU ; Jian Jun NIU
Chinese Journal of Preventive Medicine 2022;56(4):464-467
		                        		
		                        			
		                        			Objective: To evaluate the safety and immunogenicity of hepatitis E vaccine(HEV)in Maintenance hemodialysis(MHD)patients. Methods: Based on an open-labeled controlled trial, from May 2016 to March 2018, 35 eligible MHD patients were recruited in the Hemodialysis Center of Zhongshan Hospital Affiliated to Xiamen University as the experimental group, and 70 MHD patients with matched age, gender and underlying diseases as the control group. The experimental group received HEV at 0, 1 and 6 months according to the standard vaccination procedures, while the control group received routine diagnosis and treatment without vaccine and placebo injection to observe the safety and immunogenicity of the vaccine. The safety of vaccine in MHD population was evaluated by the incidence of adverse reactions/events in the experimental and control groups. The immunogenicity of HEV in MHD patients was evaluated by comparing the data from the phase Ⅲ clinical trial. Results: The overall incidence of adverse reactions/events was 17.1% (18/105), and there were no grade 3-4 adverse reactions/events related to vaccination. In the experimental group, the incidence of local adverse reactions/events was 20.0% (7/35), and the incidence of systemic adverse reactions/events was 17.1% (6/35).There was no significant difference in the incidence of systemic adverse reactions/events between the experimental group and the control group (P>0.05). There were 23 patients receiving 3 doses with the standard schedule. The positive rate of HEV-IgG antibody was 100% and the GMC was 14.47(95%CI:13.14-15.80) WU/ml, which showed no significant difference compared with the 46 patients in Phase Ⅲ clinical trial (t=-1.04, P>0.05). Conclusion: Recombinant HEV has good safety and immunogenicity in MHD patients.
		                        		
		                        		
		                        		
		                        			Clinical Trials, Phase III as Topic
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Hepatitis E
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Immunogenicity, Vaccine
		                        			;
		                        		
		                        			Immunoglobulin G
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Renal Dialysis
		                        			;
		                        		
		                        			Viral Hepatitis Vaccines/adverse effects*
		                        			
		                        		
		                        	
9.Immunogenicity of Whole
Shi Qi XIAO ; Da XU ; Hong Yang DUAN ; Xue Ting FAN ; Gui Lian LI ; Wen ZHANG ; Ma Chao LI ; Na HAN ; Xin Yao LI ; Na LI ; Li Lan ZHAO ; Xiu Qin ZHAO ; Kang Lin WAN ; Hai Can LIU ; Wen Hai FENG
Biomedical and Environmental Sciences 2021;34(7):528-539
		                        		
		                        			Objectives:
		                        			To evaluate the immunogenicity of 
		                        		
		                        			Methods:
		                        			Protein extracts from 
		                        		
		                        			Results:
		                        			Immunization with 
		                        		
		                        			Conclusion
		                        			This is the advanced study to investigate the immunogenicity of
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Antibodies, Bacterial/immunology*
		                        			;
		                        		
		                        			Antigens, Bacterial/immunology*
		                        			;
		                        		
		                        			Bacterial Proteins/immunology*
		                        			;
		                        		
		                        			Cross Reactions
		                        			;
		                        		
		                        			Cytokines/immunology*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Genome, Bacterial
		                        			;
		                        		
		                        			Immunoglobulin G/immunology*
		                        			;
		                        		
		                        			Immunoglobulin M/immunology*
		                        			;
		                        		
		                        			Macrophages/immunology*
		                        			;
		                        		
		                        			Mice, Inbred BALB C
		                        			;
		                        		
		                        			Mycobacterium avium Complex/immunology*
		                        			;
		                        		
		                        			Mycobacterium tuberculosis/immunology*
		                        			;
		                        		
		                        			Tuberculosis Vaccines/administration & dosage*
		                        			;
		                        		
		                        			Whole Genome Sequencing
		                        			
		                        		
		                        	
10.Serological Identification and FUT1 Gene Mutation Analysis of 8 Individuals with Para-Bombay Phenotypes in Guangxi.
Jin-Lian LIU ; Xue-Jun LIU ; Ting-Ting MA ; Jie-Run CHEN ; Li-Lan LI
Journal of Experimental Hematology 2021;29(4):1318-1324
		                        		
		                        			OBJECTIVE:
		                        			To study the serological characteristics and molecular biological basis of 8 individuals with Para-Bombay phenotypes in Guangxi area.
		                        		
		                        			METHODS:
		                        			Serological tests were used to identify the blood groups of red cells. Molecular biological methods, including PCR-SSP for ABO genotyping and DNA sequencing for FUT1, were used to detect the genotypes of ABO and FUT1 which determined the expression of H antigen.
		                        		
		                        			RESULTS:
		                        			Eight individuals in the study were all the Para-Bombay phenotypes, including 4 cases of B
		                        		
		                        			CONCLUSION
		                        			There are varieties of molecular genetic mechanisms for Para-Bombay phenotypes. In this study, the FUT1 mutations that cause Para-Bombay phenotypes in Guangxi area are mainly h3, h
		                        		
		                        		
		                        		
		                        			ABO Blood-Group System/genetics*
		                        			;
		                        		
		                        			Alleles
		                        			;
		                        		
		                        			China
		                        			;
		                        		
		                        			Fucosyltransferases/genetics*
		                        			;
		                        		
		                        			Genotype
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Mutation
		                        			;
		                        		
		                        			Phenotype
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail